The high-speed train now has a new builder onboarded for the project. Photo of the N700 courtesy of © JR Central

The Texas high-speed train that plans to zip between Houston and Dallas still has some obstacles to plow through, but the project now has a builder at least.

Texas Central, the developer of the Texas Bullet Train, has signed a contract with Salini Impregilo, an Italian construction company and one of the largest civil engineering contractors in the world, and its American subsidiary, Lane Construction.

"This agreement brings us one step closer to beginning construction of the civil infrastructure segments of the project," said Texas Central CEO Carlos F. Aguilar, in a release.

The train still can't move forward because it doesn't own all of the land necessary for the route.

But if/when it does get the land, Salini Impregilo will do the following:

  • supply the civil and infrastructure scope, including the design and construction of the viaduct and embankment sections along the entire route
  • install the track system
  • oversee alignment and construction of all buildings and services that will house maintenance and other rail system equipment

Salini-Lane had previously provided front-end engineering and design for the train's civil infrastructure, as well as an analysis of construction costs and schedule estimates.

"Salini-Lane's unmatched track record with rail infrastructure and, very specifically, its world-class high-speed rail expertise across the globe will be central to the completion of America's first end-to-end high-speed rail system," Aguilar says.

Salini's CEO Pietro Salini says in a statement that the company is both thrilled and honored to bring its large-scale railway expertise to the project.

Salini Impregilo is active in more than 50 countries on five continents, with experience building more than 4,000 miles of railway infrastructure around the world. It has built high-speed train projects in Europe and some iconic projects in the world, including the expansion of the Panama Canal.

Although the company has worked in the U.S. since the 1980s, it expanded its presence in 2016 when it merged with The Lane Construction Corporation, a U.S.-based company with almost 130 years of experience in infrastructure work.

The Texas train will be based on Central Japan Railway's Tokaido Shinkansen train system, which is considered the safest mass transportation system in the world.

The system has transported more than 10 billion passengers in 54-plus years, with no fatalities or injuries from operations, and has an impeccable on-time performance record.

It will debut a new train, the Shinkansen N700S, the sixth generation of this train, before the 2020 Olympics.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”